Sulfonylureas and Glinides Exhibit Peroxisome Proliferator-Activated Receptor γ Activity: A Combined Virtual Screening and Biological Assay Approach

2006 ◽  
Vol 71 (2) ◽  
pp. 398-406 ◽  
Author(s):  
Marco Scarsi ◽  
Michael Podvinec ◽  
Adrian Roth ◽  
Hubert Hug ◽  
Sander Kersten ◽  
...  
2021 ◽  
Vol 25 (2) ◽  
pp. 117-132
Author(s):  
Merilin Al Sharif ◽  
◽  
Petko Alov ◽  
Vessela Vitcheva ◽  
Antonia Diukendjieva ◽  
...  

Triterpenoids are well known metabolic syndrome (MetS) modulators. One of the suggested molecular mechanisms of action involves peroxisome proliferator-activated receptor gamma (PPARγ) activation. In this study we aimed to: (i) develop a virtual screening (VS) protocol for PPARγ weak partial agonists, (ii) predict potential metabolic transformations of naturally-derived triterpenoids, and (iii) perform VS of the triterpenoids and their metabolites. The NIH PubMed system was searched for publications about naturally-derived oleanane triterpenoids which are agonists or up-regulators of PPARγ. Structure- and ligand-based methods were combined in the development of the VS protocol. Metabolites were predicted using Meteor Nexus expert system (Lhasa Limited). Two in-house virtual libraries of PPARγ weak partial agonists and naturally-derived triterpenoids with their predicted metabolites were compiled. The pharmacophore-based docking protocol was applied for VS of the collected triterpenoids. Most of the docking poses reproduced the binding mode of caulophyllogenin (a weak partial agonist) in a complex with PPARγ (PDB ID 5F9B). Our results contribute to the mechanistic explanation of the effects of triterpenoids suggesting possible weak partial agonistic activity toward PPARγ. This research can direct further studies on triterpenoids’ role in MetS modulation. The developed protocol can be applied for VS of any PPARγ weak partial agonists.


PPAR Research ◽  
2010 ◽  
Vol 2010 ◽  
pp. 1-10 ◽  
Author(s):  
Stephanie N. Lewis ◽  
Josep Bassaganya-Riera ◽  
David R. Bevan

Virtual screening (VS) is a discovery technique to identify novel compounds with therapeutic and preventive efficacy against disease. Our current focus is on the in silico screening and discovery of novel peroxisome proliferator-activated receptor-gamma (PPARγ) agonists. It is well recognized that PPARγagonists have therapeutic applications as insulin sensitizers in type 2 diabetes or as anti-inflammatories. VS is a cost- and time-effective means for identifying small molecules that have therapeutic potential. Our long-term goal is to devise computational approaches for testing the PPARγ-binding activity of extensive naturally occurring compound libraries prior to testing agonist activity using ligand-binding and reporter assays. This review summarizes the high potential for obtaining further fundamental understanding of PPARγbiology and development of novel therapies for treating chronic inflammatory diseases through evolution and implementation of computational screening processes for immunotherapeutics in conjunction with experimental methods for calibration and validation of results.


RSC Advances ◽  
2021 ◽  
Vol 11 (1) ◽  
pp. 147-159
Author(s):  
Zhiwei Yang ◽  
Yizhen Zhao ◽  
Dongxiao Hao ◽  
He Wang ◽  
Shengqing Li ◽  
...  

Offering a new strategy for resurrecting PPARγ-targeted therapeutics to chemoprevention, by taking the conformational plasticity of the receptor into account in the virtual screening procedure.


2012 ◽  
Vol 55 (11) ◽  
pp. 4978-4989 ◽  
Author(s):  
Daniel K. Nevin ◽  
Martin B. Peters ◽  
Giorgio Carta ◽  
Darren Fayne ◽  
David G. Lloyd

ChemMedChem ◽  
2017 ◽  
Vol 12 (16) ◽  
pp. 1399-1407 ◽  
Author(s):  
Ugo Perricone ◽  
Marcus Wieder ◽  
Thomas Seidel ◽  
Thierry Langer ◽  
Alessandro Padova ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document